Market Cap 3.30M
Revenue (ttm) 0.00
Net Income (ttm) -7.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 24,300
Avg Vol 130,346
Day's Range N/A - N/A
Shares Out 1.33M
Stochastic %K 92%
Beta 0.41
Analysts Strong Sell
Price Target $34.00

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 933 3121
Fax: 972 3 509 7196
Address:
4 Oppenheimer Street, Science Park, Rehovot, Israel
Dr_HIM
Dr_HIM Jul. 7 at 7:00 PM
$PPBT Tase is like a shark treading water 50 meters off the coastline 🌊🦈 Smelled blood but can’t find its prey 🖕🏽
0 · Reply
Duediligence20
Duediligence20 Jul. 7 at 6:59 PM
$PPBT When is the last time you saw Company Directors buying shares here? Oh yea that’s right they probably have a Non Disclosure Agreement prohibiting that🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣. Plus this is probably Top Secret Shit involved with the Cancer Moon Shot.🤦‍♂️🤦‍♂️🤦‍♂️
0 · Reply
Oxinternet
Oxinternet Jul. 7 at 3:57 PM
$PPBT If you just threw $1M at this and came back 10 years later, you’d probably have $999,999. 🙄
1 · Reply
Smittysixty
Smittysixty Jul. 7 at 3:53 PM
$PPBT Catalysts on Deck 🚨 📆 Q2 Financials + 13Fs due by Aug 15 🧪 CM24 Ph2b initiation expected any day now 📑 ESMO abstract titles: • Regular – July 25 • Late-breaking – Sept 20 🎤 ESMO Congress: Oct 17–21 NT219: Unfinished Story 🧩 ~75% of clinical data still unreleased from the Ph1/2 trial that wrapped 425 days ago 🔍 What’s still under wraps: • 8 SCCHN patients • 27 monotherapy patients • Colorectal combo cohort (n=?) Silent data. Ticking clock. Catalysts stacking. FUD Patrol distracting.
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 7 at 3:03 PM
$PPBT it’s not quiet for $IMRX 🚀
0 · Reply
Mattblock
Mattblock Jul. 7 at 2:58 PM
$PPBT enjoying the quietness
0 · Reply
PurpleDreamer
PurpleDreamer Jul. 7 at 2:34 PM
$PPBT High volume early in the morning...one of these days....
0 · Reply
Duediligence20
Duediligence20 Jul. 7 at 1:49 PM
$PPBT Keep The Hope Light On People. “These results not only validate CM24’s potential but also position Purple Biotech to expand its pipeline into broader cancer applications. With a planned Phase 2b trial targeting high-CEACAM1 patients, the company is tapping into precision oncology—a sector that continues to draw investor enthusiasm due to its game-changing innovation.” We know when will the rest of the world discover us or are we being played?🤔
1 · Reply
Stocksavior14
Stocksavior14 Jul. 7 at 1:25 PM
$PPBT the permabulls will be right about the deals when pigs officially have wings coming out of their bodies LOL
0 · Reply
Smittysixty
Smittysixty Jul. 7 at 1:10 PM
$PPBT 🚨 Big NT219 Data Gaps 🚨 Phase 1/2 trial ended May 8, 2024 — 425 days ago Last data shared: Feb 26, 2024 at ESMO TAT Only ~25% of efficacy data has been disclosed 📉 8 SCCHN patient data remains 📉 27 patients in NT219 monotherapy arm 📉 Colorectal combo arm (patient count undisclosed) 📉 No DoR, PFS, OS 👀 Yet Phase 2 already initiated 💡 All eyes now on ESMO Congress 2025 for the full reveal
0 · Reply
Latest News on PPBT
Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025, 7:10 AM EDT - 6 weeks ago

Purple Biotech Reports First Quarter 2025 Financial Results


Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025, 7:30 AM EDT - 2 months ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer


Why Is Purple Biotech Stock Trading Higher On Monday?

Dec 2, 2024, 9:18 AM EST - 7 months ago

Why Is Purple Biotech Stock Trading Higher On Monday?


Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 7:00 AM EST - 8 months ago

Purple Biotech Reports Third Quarter 2024 Financial Results


Purple Biotech Reports First Quarter 2024 Financial Results

May 21, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2024 Financial Results


Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Feb 1, 2024, 7:30 AM EST - 1 year ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219


Purple Biotech Reports Third Quarter 2023 Financial Results

Nov 21, 2023, 6:50 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2023 Financial Results


Purple Biotech Reports Second Quarter 2023 Financial Results

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results


Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron


Purple Biotech Reports Third Quarter 2022 Financial Results

Nov 8, 2022, 7:53 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2022 Financial Results


Purple Biotech Appoints Lior Fhima as Chief Financial Officer

Nov 2, 2022, 7:37 AM EDT - 2 years ago

Purple Biotech Appoints Lior Fhima as Chief Financial Officer


Purple Biotech Reports Second Quarter 2022 Financial Results

Aug 4, 2022, 7:30 AM EDT - 3 years ago

Purple Biotech Reports Second Quarter 2022 Financial Results


Purple Biotech Announces Executive Leadership Changes

Jul 14, 2022, 7:30 AM EDT - 3 years ago

Purple Biotech Announces Executive Leadership Changes


Dr_HIM
Dr_HIM Jul. 7 at 7:00 PM
$PPBT Tase is like a shark treading water 50 meters off the coastline 🌊🦈 Smelled blood but can’t find its prey 🖕🏽
0 · Reply
Duediligence20
Duediligence20 Jul. 7 at 6:59 PM
$PPBT When is the last time you saw Company Directors buying shares here? Oh yea that’s right they probably have a Non Disclosure Agreement prohibiting that🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣. Plus this is probably Top Secret Shit involved with the Cancer Moon Shot.🤦‍♂️🤦‍♂️🤦‍♂️
0 · Reply
Oxinternet
Oxinternet Jul. 7 at 3:57 PM
$PPBT If you just threw $1M at this and came back 10 years later, you’d probably have $999,999. 🙄
1 · Reply
Smittysixty
Smittysixty Jul. 7 at 3:53 PM
$PPBT Catalysts on Deck 🚨 📆 Q2 Financials + 13Fs due by Aug 15 🧪 CM24 Ph2b initiation expected any day now 📑 ESMO abstract titles: • Regular – July 25 • Late-breaking – Sept 20 🎤 ESMO Congress: Oct 17–21 NT219: Unfinished Story 🧩 ~75% of clinical data still unreleased from the Ph1/2 trial that wrapped 425 days ago 🔍 What’s still under wraps: • 8 SCCHN patients • 27 monotherapy patients • Colorectal combo cohort (n=?) Silent data. Ticking clock. Catalysts stacking. FUD Patrol distracting.
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 7 at 3:03 PM
$PPBT it’s not quiet for $IMRX 🚀
0 · Reply
Mattblock
Mattblock Jul. 7 at 2:58 PM
$PPBT enjoying the quietness
0 · Reply
PurpleDreamer
PurpleDreamer Jul. 7 at 2:34 PM
$PPBT High volume early in the morning...one of these days....
0 · Reply
Duediligence20
Duediligence20 Jul. 7 at 1:49 PM
$PPBT Keep The Hope Light On People. “These results not only validate CM24’s potential but also position Purple Biotech to expand its pipeline into broader cancer applications. With a planned Phase 2b trial targeting high-CEACAM1 patients, the company is tapping into precision oncology—a sector that continues to draw investor enthusiasm due to its game-changing innovation.” We know when will the rest of the world discover us or are we being played?🤔
1 · Reply
Stocksavior14
Stocksavior14 Jul. 7 at 1:25 PM
$PPBT the permabulls will be right about the deals when pigs officially have wings coming out of their bodies LOL
0 · Reply
Smittysixty
Smittysixty Jul. 7 at 1:10 PM
$PPBT 🚨 Big NT219 Data Gaps 🚨 Phase 1/2 trial ended May 8, 2024 — 425 days ago Last data shared: Feb 26, 2024 at ESMO TAT Only ~25% of efficacy data has been disclosed 📉 8 SCCHN patient data remains 📉 27 patients in NT219 monotherapy arm 📉 Colorectal combo arm (patient count undisclosed) 📉 No DoR, PFS, OS 👀 Yet Phase 2 already initiated 💡 All eyes now on ESMO Congress 2025 for the full reveal
0 · Reply
SirGay_LoveRaw
SirGay_LoveRaw Jul. 7 at 8:16 AM
$PPBT What if this board was right predicting every single buyout deal, but then the Big Pharma lawyers were like: - You promised secrecy, and then you leak the deal on a ST board!!! - We didn't leak anything, I promise, the pocket tweet was a honest mistake, the Toblerone was just chocolate... - We don't believe you, the deal is canceled!
0 · Reply
Stocksavior14
Stocksavior14 Jul. 6 at 3:49 AM
$PPBT so you’re going to donate 99% of what you might make here? LOL
0 · Reply
St0ckPwn
St0ckPwn Jul. 6 at 12:33 AM
$PPBT 7 months and counting without a single green candle in sight
1 · Reply
Randy_Lahey_Trevor_Corey
Randy_Lahey_Trevor_Corey Jul. 5 at 6:02 PM
$PPBT if I make any money in my lifetime off this stock I’ll donate $17 to the nearest synagogue
0 · Reply
Purplepayday
Purplepayday Jul. 4 at 3:52 PM
$PPBT Halted on Tase… And halted here on Nasdaq 🤔 That can only mean one thing 🧐 …
2 · Reply
PPBT4LYFE
PPBT4LYFE Jul. 3 at 8:49 PM
$PPBT another week closer. Markets closed tomorrow.
1 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 3 at 2:55 PM
$NVCR is undervalued. But if you want to invest in much hotter pancreatic cancer biotechs then $IMRX & $PPBT are much more exciting short & long 🚀 GLB 👍 ☘️ 🐂
0 · Reply
Smittysixty
Smittysixty Jul. 3 at 2:50 PM
$PPBT Let’s assume that NT-219 full phase 1/2 data will drop at ESMO (LBA titles Sept 20). Hard to picture a billion-dollar NT-219 deal when Purple trades at $7M… unless a CM-24 transaction rewrites the narrative first. Value isn’t just in the data. It’s in the timing. ⏳ Clock’s ticking on CM-24.
0 · Reply
Smittysixty
Smittysixty Jul. 3 at 2:47 PM
$PPBT 421 days since NT-219 Phase 1/2 completed. Still no full results. 100mg cohort? Silent. ESMO abstracts drop Sept 20. The most likely venue for it IMO.
1 · Reply
Smittysixty
Smittysixty Jul. 3 at 12:11 AM
$PPBT If anonymous FUD accounts spent a fraction of their time researching the science instead of attacking those who do, they might actually build confidence in the stock. But that’s not their game. They don’t focus on the company—they fixate on silencing anyone sharing facts. That says more about their motives than it does about mine.
2 · Reply
LarryHParker
LarryHParker Jul. 2 at 9:52 PM
2 · Reply
LarryHParker
LarryHParker Jul. 2 at 9:51 PM
$PPBT 🤣
4 · Reply